For favorable and intermediate or poor risk RCC, first-line treatments are combination therapies (ICI + / - targeted therapy or a 2nd ICI); combinations include axitinib + pembrolizumab, cabozantinib + nivolumab, levantinib + pembrolizumab, and ipilimumab + nivolumab.